Cargando…

Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma

Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a germline BRCA1 mutation and a stage IV OCS who was proposed olaparib maintenance therapy after three platinum-based chemotherapies in relapse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magalhães, Denise, Bartosch, Carla, Abreu, Miguel H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357426/ https://www.ncbi.nlm.nih.gov/pubmed/35949745 http://dx.doi.org/10.7759/cureus.26662

Ejemplares similares

Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022)

Expression of Poly(Adenosine Diphosphate-Ribose) Polymerase Protein in Breast Cancer
por: Akanksha,, et al.
Publicado: (2022)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
por: Ström, Cecilia E., et al.
Publicado: (2012)

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors
por: Cseh, Anna Mária, et al.
Publicado: (2017)

The Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor PJ34 Reduces Pulmonary Ischemia-Reperfusion Injury in Rats
por: Hatachi, Go, et al.
Publicado: (2014)

Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis
por: Qiao, Weiqiang, et al.
Publicado: (2017)

Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats
por: Khin Hnin Si, May, et al.
Publicado: (2013)

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition
por: Audeh, M William
Publicado: (2014)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
por: Cheng, Hongyan, et al.
Publicado: (2021)

4-Thioribose Analogues of Adenosine Diphosphate Ribose (ADPr) Peptides
por: Madern, Jerre M., et al.
Publicado: (2023)

Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells
por: Sargazi, Saman, et al.
Publicado: (2019)

Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer With BRCA Gene Mutations: A Narrative Review
por: Jain, Prateek
Publicado: (2023)

Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells
por: Jeong, Keun-Yeong, et al.
Publicado: (2022)

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
por: Sha, Huanhuan, et al.
Publicado: (2021)

Total Synthesis of a Cyclic Adenosine 5′-Diphosphate Ribose Receptor Agonist
por: Swarbrick, Joanna M., et al.
Publicado: (2012)

Synthesis of phosphonoacetate analogues of the second messenger adenosine 5′-diphosphate ribose (ADPR)
por: Baszczyňski, Ondřej, et al.
Publicado: (2020)

Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report
por: Wang, Zheng, et al.
Publicado: (2021)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
por: Ni, Jing, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis
por: Luo, Jing, et al.
Publicado: (2022)

Synthesis of Terminal Ribose Analogues of Adenosine 5′-Diphosphate Ribose as Probes for the Transient Receptor Potential Cation Channel TRPM2
por: Baszczyňski, Ondřej, et al.
Publicado: (2019)

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair
por: Gou, Rui, et al.
Publicado: (2022)

Cyclic Adenosine 5′-Diphosphate Ribose Analogs without a “Southern” Ribose Inhibit ADP-ribosyl Cyclase–Hydrolase CD38
por: Swarbrick, Joanna M., et al.
Publicado: (2014)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
por: Pletcher, Jerred P., et al.
Publicado: (2021)

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
por: Ni, Jing, et al.
Publicado: (2022)

Programmed death ligand 1, poly adenosine diphosphate ribose polymerase, and vascular endothelial growth factor receptor inhibition: a potential combination regimen for targeting triple-negative breast cancer?
por: Abdul Wahid, Maryam, et al.
Publicado: (2023)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Blocking Cyclic Adenosine Diphosphate Ribose-mediated Calcium Overload Attenuates Sepsis-induced Acute Lung Injury in Rats
por: Peng, Qian-Yi, et al.
Publicado: (2016)

Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment
por: Jeong, Keun-Yeong, et al.
Publicado: (2021)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1
por: Xue, Dong-Dong, et al.
Publicado: (2023)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7che2djnc321qijhrc3ja45v7h